How has been the historical performance of Medicamen Organ.?

Answer:The historical performance of Medicamen Organ shows significant growth in various financial metrics from March 2024 to March 2025. Breakdown: Medicamen Organ's net sales increased from 25.27 Cr in March 2024 to 38.19 Cr in March 2025, contributing to a total operating income rise to 38.19 Cr from 25.27 Cr. The company's total expenditure also grew, reaching 31.60 Cr from 20.53 Cr, primarily driven by higher raw material costs, which rose to 22.25 Cr from 14.40 Cr. Operating profit (PBDIT) improved to 6.69 Cr from 5.81 Cr, although the operating profit margin decreased slightly to 17.26% from 18.76%. Profit before tax increased to 5.43 Cr from 4.44 Cr, leading to a profit after tax of 4.05 Cr, up from 2.62 Cr. The company's earnings per share rose to 3.46 from 3.05, while the book value per share increased to 25.11 from 17.74. On the balance sheet, total assets grew to 59.21 Cr from 38.44 Cr, with total liabilities also increasing to 59.21 Cr from 38.44 Cr. Cash flow from financing activities saw a notable increase to 10.00 Cr from 4.00 Cr, resulting in a net cash inflow of 3.00 Cr compared to no inflow in the previous year. Overall, Medicamen Organ demonstrated a strong financial performance with growth across key metrics.